The Foundation Fighting Blindness has awarded Applied Genetic Technologies a $1.5 million grant for pre-clinical trials for a gene therapy treatment it is developing.
The grant will allow the company, located in the Progress Corporate Park, to complete testing of a treatment for X-linked Retinoschisis—a genetic eye disease and the leading cause of juvenile macular degeneration in males —in animals and finish safety studies required to proceed to human clinical trials. No treatment for the disease is currently available.
AGTC is creating treatments for “orphan diseases,” says AGTC CEO and President Susan Washer. “We’re thrilled that the foundation has acknowledged AGTC’s expertise in development of treatments for rare genetic disease,” Washer says.